Dupont Capital Management Corp raised its stake in Masimo Co. (NASDAQ:MASI) by 20.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,304 shares of the medical equipment provider’s stock after acquiring an additional 1,744 shares during the period. Dupont Capital Management Corp’s holdings in Masimo were worth $1,425,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of MASI. FMR LLC boosted its stake in Masimo by 17.8% in the fourth quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock valued at $417,622,000 after acquiring an additional 587,587 shares during the period. Norges Bank acquired a new position in Masimo in the fourth quarter valued at approximately $53,357,000. Fundsmith LLP acquired a new position in Masimo in the fourth quarter valued at approximately $51,470,000. Lord Abbett & CO. LLC acquired a new position in Masimo in the fourth quarter valued at approximately $31,807,000. Finally, Scout Investments Inc. boosted its stake in Masimo by 101.2% in the fourth quarter. Scout Investments Inc. now owns 545,828 shares of the medical equipment provider’s stock valued at $58,606,000 after acquiring an additional 274,485 shares during the period. Institutional investors own 83.67% of the company’s stock.
In related news, Director Steven Barker sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the sale, the director now owns 74,832 shares of the company’s stock, valued at $10,102,320. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jon Coleman sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $280,000.00. Following the sale, the insider now directly owns 13,201 shares in the company, valued at approximately $1,848,140. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,695 shares of company stock worth $5,006,550. 11.50% of the stock is owned by corporate insiders.
Several brokerages have recently issued reports on MASI. Stifel Nicolaus boosted their price objective on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Piper Jaffray Companies boosted their price objective on Masimo from $148.00 to $160.00 in a research report on Friday, May 17th. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 14th. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective for the company in a research report on Wednesday, May 8th. Finally, UBS Group boosted their price objective on Masimo from $147.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Masimo has an average rating of “Buy” and a consensus target price of $154.25.
Shares of NASDAQ MASI traded down $2.24 during midday trading on Wednesday, hitting $137.14. 217,759 shares of the company’s stock were exchanged, compared to its average volume of 448,870. The company has a market cap of $7.43 billion, a PE ratio of 45.26, a P/E/G ratio of 2.78 and a beta of 1.12. Masimo Co. has a twelve month low of $96.14 and a twelve month high of $147.91.
Masimo (NASDAQ:MASI) last announced its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The firm had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $223.67 million. During the same quarter in the previous year, the company earned $0.75 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. As a group, equities research analysts forecast that Masimo Co. will post 3.12 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Sundance Herald and is the property of of Sundance Herald. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://sundanceherald.com/2019/05/29/dupont-capital-management-corp-raises-stake-in-masimo-co-masi.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: Why do companies issue stock splits?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.